Search results
7 maj 2022 · After initiation of our trial, a multicentre, open-label, randomised, phase 2 trial of imiquimod versus cidofovir for the treatment of VIN was published. It was shown that both drugs are active, safe, and feasible for treatment of VIN and warrant further investigation.
7 maj 2022 · Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open-label, randomised, phase 2 trial
1 lis 2020 · In a 2016 Cochrane review of medical and surgical interventions for the treatment of VIN, Lawrie et al. [33] recommended surgical excision as second-line therapy for patients who fail to respond to medical treatment. That said, first-line surgical excision (preferably superficial vulvectomy) of small, well-circumscribed lesions would probably ...
Treatment is recommended for all women with vulvar HSIL (VIN usual type). Because of the potential for occult invasion, wide local excision should be performed if cancer is suspected, even if biopsies show vulvar HSIL.
The immunomodulator, imiquimod, has been proposed as a medical alternative to surgical treatments. We performed a systematic review and meta-analysis to determine the efficacy of topical imiquimod on the treatment of high-grade vulvar intraepithelial neoplasia (VIN 2 and VIN 3).
The aim of this randomised clinical trial was to compare the clinical efectiveness, histological response, HPV clearance, acceptance, and psychosexual morbidity of primary imiquimod treatment versus surgical treatment in women with vHSIL.
29 mar 2023 · Vulval intraepithelial neoplasia (VIN) is a skin condition of the vulva. Find out about symptoms and treatment options.
